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Introduction 
Clomifene citrate has been the first-line medical treatment 
for polycystic ovarian syndrome-related (WHO class II) 
infertility for over 30 years. It acts by up-regulating follicle 
stimulating hormone, which encourages follicular 
development (Wallach & Adashi, 1984). However, more 
than one follicle may result, thus increasing the risk of 
multiple pregnancy from the background rate of 1.6% to 
approximately 5–8% 
(Legro, 2016; Office for National Statistics, 2017). The 
majority are dichorionic twins, with the risk of triplets 
reported as 0.3–0.5%, quadruplets 0.3% and quintuplets 
0.13% (McDowell, Kroon, & Yazdani, 2013). 
It is well established that multiple pregnancies are 
associated with adverse maternal, fetal and neonatal 
outcomes. To address this risk, clomifene should be 
prescribed at the lowest ovulatory dose. The conventional 
starting dose is 50 mg daily, for 5 days in the follicular 
phase. Assessment of serum mid-luteal progesterone 
might then be used to confirm whether ovulation has 
occurred, allowing a dose increase in the subsequent cycle 
if not. 
The National Institute for Health and Care Excellence 
(NICE) does not advise the use of mid-luteal progesterone 
assessment for patients taking clomifene, but gives this 
guidance (National Institute for Health and Care 
Excellence, 2013): 
For women who are taking clomifene citrate, offer 
ultrasound monitoring during at least the first cycle of 
treatment to ensure that they are taking a dose that 
minimises the risk of multiple pregnancy. (1.5.2.3, Clinical 
Guideline 156) 
 The Royal College of Obstetricians and 
Gynaecologists has recommended serial ultrasound 
monitoring for clomifene-associated follicular 
development since 1998, and NICE adopted the guideline 
in 2004 (National 
Institute for Clinical 




It is based on expert 
opinion rather than 
research evidence. A 
systematic review cast 
doubt upon the advice, 
concluding that there is 
insufficient data to 
support its use (Galazis, 
Zertalis, Haoula, & Atiomo, 2011). The rationale for 
ultrasound monitoring is to detect multifollicular 
development and enable 
ABSTRACT 
The National Institute for Health and Care Excellence Clinical Guideline 156 advises that transvaginal 
ultrasonography (TVUS) should be used in the first cycle of treatment with clomifene citrate, to assess 
for multifollicular development and hence the risk of multiple pregnancy. This guidance is based on 
expert opinion rather than research evidence. We conducted a cross-sectional online and postal 
survey among UK-based consultant gynaecologists and fertility specialists, to explore compliance with 
this guideline. A total of 110 responses met the inclusion criteria. During first-cycle treatment with 
clomifene, 50.9% of respondents were not always using TVUS, and 21.8% never were. Clinicians who 
did not have immediate access to TVUS were significantly less likely to scan (p < 0.01). Other key factors 
influencing practice were, personal experience of the clinician, lack of an evidence base to support the 
guideline and a willingness to accept the risk of multiple pregnancy. Several respondents questioned 
the value of scanning the first cycle only and highlighted that over-response may be seen in 
subsequent cycles. This study confirms that there is variation in adherence to the guideline and 
uncertainty about the clinical need for scan monitoring. Further evidence to support or refute the 
guideline is required. 
  
Figure 1. Questions from the paper-based survey. 
the clinician to advise abstinence from intercourse during 
an affected cycle. Opponents argue that monitoring is 
expensive, cannot prevent intercourse in women who 
have multifollicular development, and that evidence of 
improved outcomes is lacking. The guideline also limits 
clomifene use to settings where timely transvaginal 
ultrasonography (TVUS) is available, hence it is now rarely 
prescribed in primary care (OpenPrescribing.net, 2018; 
Wilkes, Chinn, Murdoch, & Rubin, 2009). 
Anecdotal evidence suggests that the NICE guideline for 
TVUS is not always followed. To investigate this 
contentious issue further, we conducted a survey of UK-
based consultant gynaecologists and fertility specialists. 
Materials and methods 
Participants 
The target sample population was UK-based consultant 
gynaecologists and fertility specialists who currently 
prescribe clomifene for ovulatory disorders. 
Survey design 
The online survey was developed using SurveyMonkey 
(www.surveymonkey.com). The primary outcome data 
related to the likelihood of using TVUS during the first cycle 
of clomifene therapy. For simplicity, respondents working 
in both the NHS and the private sector were asked to relate 
their answers to NHS work only. The survey was piloted 
with two experts in reproductive medicine, and minor 
adjustments made (Figure 1). 
Distribution 
Publicly available professional email addresses were found 
by searching online. A link to the online survey was sent to 
893 consultant gynaecologists in April 2017, followed by a 
reminder email after three weeks.. The link was also 
published in the British Fertility Society (BFS) newsletter, 
and by Fertility Network UK via twitter. A comparable 
postal survey was sent to the Clinical Director of each of 
the 86 Human 
Fertilisation and Embryology Authority (HFEA)-licenced 
fertility units in the UK, and the Clinical Director for 
Gynaecology in each of the 140 NHS trusts providing 
gynaecology services in England. The postal survey was 
distributed on 28 July 2017. The postal and online surveys 
remained open until 07 September 2017. All responses 
were anonymous. 
Analysis 
A concurrent triangulation strategy was used comprising 
cross-validation of quantitative data with qualitative 
findings (Cresswell & Plano-Clark, 2003). Nominal, 
Table 1. Proportion of respondents stating their routine use of 
TVUS for multiple pregnancy risk, and/or serum mid-luteal 





Which of the following best describes your role? 
 Consultant Obstetrician/Gynaecologist 
 Specialty trainee (ST3 or above) 
 Specialty trainee (ST1-ST2) 
 Staff grade or associate specialist 
 Trainee doctor in specialty other than O&G 
 Specialist nurse 
 Other (please specify) 
Do you work with NHS patients or in the private sector? 
 NHS only 
 Private sector only 
 Both NHS and private (Please answer the rest of the 
survey in relation to your NHS work) 
In which settings do you prescribe clomifene? 
 In a dedicated fertility service WITH immediate 
access to ultrasound 
 In a dedicated fertility service WITHOUT immediate 
access to ultrasound 
 In a general gynaecology outpatient clinic 
 In a community-based gynaecology service 
In an average month, how many first-cycle clomifene 





In the routine management of NHS patients taking their first 
cycle of clomifene, how often would you arrange: 
5.1 An ultrasound scan for multifollicular development (i.e. 
for multiple pregnancy risk)? 
5.2 Serum mid-luteal progesterone level as a marker of 
ovulation? 
Options: never, rarely, occasionally, sometimes, frequently, 
usually, always 
What are your thoughts about monitoring for multiple 
pregnancy risk after clomifene use?  
NICE advises the use of TVUS during the first cycle of 
treatment. Do you have any thoughts regarding this? 
Do you have local guidelines regarding first-cycle clomifene 
use? 
If yes, are you aware of the content of local guidelines 
regarding monitoring? What would be considered a 
significant ultrasound finding in terms of multiple pregnancy 
risk? 
Please indicate the conditions for which you would prescribe 
clomifene 
 Unexplained infertility 
 Ovulatory disorders 
 Tubal damage 
 Male factors 
 
Frequency of use 
 
TVUS 
 Serum mid-luteal 
progesterone 
   
Never 24 (21.8%) 9 (8.3%) 
Rarely 11 (10.0%) 4 (3.7%) 
Occasionally 4 (3.6%) 8 (7.3%) 
Sometimes 8 (7.3%) 4 (3.7%) 
Frequently 4 (3.6%) 4 (3.7%) 
Usually 5 (4.5%) 16 (14.7%) 
Always 54 (49.1%) 64 (58.7%) 
Total number of 
respondents 
110 109 
discrete and ordinal data were processed in SPSS 
(Statistical Package for Social Sciences, version 24.0). 
Frequencies and ordinal labels were converted to 
percentages with 95% confidence intervals (CI) where 
appropriate. Spearman’s rho correlation was applied to 
look for a relationship between the use of the two 
monitoring methods. Comparative analysis was completed 
using the Pearson v2 test and Cramer’s V. A pvalue <0.05 
was considered significant. Frequency categories were 
grouped so that at least 20% of cell counts were over the 
expected cell value. Where data were missing, the 
denominator was reduced to the number of respondents. 
Free text answers were transported into NVivo Pro 
(version 11.4) for qualitative data analysis using a 
framework thematic approach. Once the survey was 
closed, qualitative responses were categorized into core 
themes by HG. A thematic framework was developed 
based on a priori issues and emergent in vivo issues to help 
ensure credibility. Themes were independently reviewed 
by KK. The framework was applied to the dataset, and a 
detailed index of data was created. This was then refined 
and related to give a descriptive and explanatory account 
of the whole dataset in concurrence with the quantitative 
findings. 
Ethical approval 
Ethical consent was obtained from the University of 
Sunderland Research Ethics Committee (000392). NHS 




Of the initial round of email invitations to the online 
survey, 219 (24.5%) were opened and 19 (2.1%) complete 
surveys were submitted. Another 40 were submitted 
following the second round of emails and endorsement by 
the BFS and Fertility Network UK; the unknown 
denominator population prevents us from reporting the 
response rate. Of the postal surveys, 70 (31.0%) were 
completed and returned. 
A total of 129 completed surveys were returned. Of 
these, 19 (14.7%) were excluded because they were not 
completed by consultants currently prescribing clomifene, 
or because key data was missing. 
Therefore, 110 surveys were included in analysis. 
Respondent characteristics 
A total of 96 respondents (87.3%) were NHS employees 
and 14 (12.7%) worked in the private sector only. Overall, 
74 (67.3%) were prescribing clomifene in a dedicated 
fertility service with immediate access to TVUS. Responses 
came from a wide geographical spread across the UK. 
Key findings 
Of 110 respondents, 54 (49.1%) were always using TVUS to 
monitor first-cycle clomifene (Table 1), therefore 56 
respondents (50.9%) were not always practicing in 
accordance with NICE Clinical Guideline 156 (95% CI 41.56–
60.24%). The overall frequency of TVUS monitoring during 
first-cycle clomifene was 61.45% (95% CI 53.26–69.64%). 
Clinicians working in a fertility service with immediate 
access to ultrasound were significantly more likely to 
always scan than those working in a fertility service 
without immediate access (47/66 versus 1/11; v2 14.62; df 
1; p < 0.01; Cramer’s V 0.427; Table 2). A significant 
difference was also seen when responses from 
gynaecology outpatient clinics and community 
gynaecology were added to the group without immediate 
ultrasound access (47/66 versus 5/33; v2 27.73; df 1; p < 
0.01; Cramer’s V 0.529). There was no significant 
difference in the management of NHS and private patients 
(48/96 versus 6/14; v2 0.25; df 1; p ¼ 0.62). 
Of 108 responses, 66 (61.1%) said that they have local 
guidelines, and 28 gave further details. All guidelines 
classed a finding of either three or four follicles significant. 
The follicular size considered significant was either not 
given, or ranged from 12 to 20 mm (n ¼ 19, mean 15.5 
mm). Other local guidelines suggested that follicles should 
be ‘mature’ or a 
‘good size’. 
When asked about the use of serum mid-luteal 
progesterone, 80 respondents (73.4%) said that they 
request it either usually (n ¼ 16) or always (n ¼ 64). There 
was a weak negative correlation between the use of 
ultrasound and serum mid-luteal progesterone 
  
fore discounted from this analysis. 
(Spearman’s rho correlation 0.24; p ¼ 0.012; 
two-sided). 
All respondents said that they prescribe clomifene for 
ovulatory disorders; 25 respondents (22.7%) indicated that 
they also use it for unexplained infertility. 
Qualitative data analysis 
Five key themes arose from free text responses: (i) using 
personal experience to justify practice, (ii) impact of 
resource availability, (iii) consideration of the evidence 
base, (iv) justification for scanning the first cycle only, and 
(v) accepting a risk of multiple pregnancy. 
Theme 1: using personal experience to justify 
practice 
Sixteen respondents specifically referred to their own 
experience. Three used their experience to justify their use 
of TVUS, while eleven referred to experience to justify 
practice that was not concordant with the guidelines; they 
never or rarely scanned first-cycle clomifene patients and 
described low or zero rates of multiple pregnancy over 
decades of prescribing: 
[Scanning] is a waste of time and often erroneous. The 
appearance of ovaries after clomifene exposure often 
looks dramatic and cycles can be cancelled unnecessarily 
… 
Respondent number: 12 (never scans) 
Theme 2: impact of resource availability 
Limited resource availability was the most commonly 
occurring theme, with 22 respondents referring to lack of 
facilities, capacity or funding: 
The massive issue is the resources. NICE is good for giving 
guidelines but ground reality is very different. Even if it is 
ideal unfortunately it is not possible to scan them
 even once. Respondent number:
 109 
(never scans) 
Theme 3: consideration of the evidence base 
Four respondents referred to the lack of evidence base for 
NICE Clinical Guideline 156: 
Although we offer U/S in 1st cycle, there is no strong 
evidence that this reduces risk of multiple pregnancies. 
You need to consider cost, time wasted for patients/staff, 
and anxiety for patient. Respondent number: 116 (always 
scans) 
Theme 4: justification for scanning the first cycle only 
There were 22 responses relating to this issue. One 
respondent said that scanning the first cycle only is 
appropriate, while 21 expressed concern. Eight 
respondents said that they scan every clomifeneinduced 
cycle. Six were scanning in the first cycle and following 
dose changes; two were scanning every cycle only when 
other risk factors for multiple pregnancy were present; and 
two were scanning only when high doses were used: 
Disagree with this advice [to only scan the first cycle], as 
multifollicular development could occur in subsequent 
ovulation induction cycles, although the risk of multiple 
pregnancy is low. Respondent number: 
91 (always scans) 
Theme 5: accepting a risk of multiple pregnancy 
Respondents who were not routinely scanning often 
described the need to make the patient aware of the risks 
of multiple pregnancy: 
Table 2. Implications of accessibility on the frequency of TVUS use following first-cycle clomifene. 
Frequency of 
use 
 Fertility service with 
immediate access to TVUS 
Fertility service without 
immediate access to TVUS 
Gynaecology outpatient or 
community clinic Total 
  
Never 6 (9.1%) 5 (45.5%) 11 (50.0%) 22 
Rarely 3 (4.5%) 5 (45.5%) 1 (4.5%) 9 
Occasionally 1 (1.5%) – 2 (9.0%) 3 
Sometimes 3 (4.5%) – 3 (13.6%) 6 
Frequently 2 (3.0%) – 1 (4.5%) 3 
Usually 4 (6.0%) – – 4 
Always 47 (71.2%) 1 (9.0%) 4 (18.2%) 52 
Total 66 11 22 99 
Significant difference seen in practice depending on access to TVUS (v2 27.73; df 1; p< 0.01; Cramer’s V 0.529). Chi-square assumes 
equal distribution of practice for each setting type (null hypothesis); this also assumes that the guideline has no influence on 
practice. Smaller sample size accounts for non-response or clinicians who prescribe in more than one setting and were there- 
 
A risk of multiple pregnancy of 8-10% discussed at 
consultation. This is agreed and accepted by pt before 
prescription. Respondent number: 37 (never scans) 
Discussion 
In this study, over half of the clinicians surveyed were not 
always using TVUS to monitor clomifene-associated 
multiple pregnancy risk, and their practice is therefore 
contrary to NICE Clinical Guideline 156. The main reasons 
cited for this were resource limitations, personal 
experience of low multiple pregnancy rates and the lack of 
an evidence base. The survey also suggested that clinicians 
and patients are often willing to accept a risk of multiple 
pregnancy with clomifene. The relevance of scanning the 
first cycle only was brought into question. Interestingly, 
22.9% of respondents indicated that they use clomifene 
for unexplained infertility, despite evidence that it is no 
more effective than expectant management (Bhattacharya 
et al., 2008; Hughes, Brown, Collins, & Vanderkerchove, 
2010). Further analysis regarding this is beyond the scope 
of this paper. 
To our knowledge, this is the first study investigating 
compliance with NICE regarding first-cycle TVUS 
monitoring during clomifene therapy. The survey collected 
responses from across the UK, from senior clinicians 
making treatment decisions. The main limitations arise 
from recruitment difficulties and a low-level response rate. 
Email invitations possibly remained unopened due to 
invalid addresses, rejection of an unknown sender domain 
or if invitees felt overburdened by emails. The response to 
the subsequent postal survey was comparable to similar 
studies in the field (Hackethal et al., 2010; Nandi, Gudi, 
Shah, & Homburg, 2015). Because of the pragmatic 
approach to recruitment based on available data, those 
working solely in the private sector were represented by a 
small sample, affecting the applicability of comparative 
analysis. Non-response analysis was not possible due to 
the limited demographic data collected; however, bias 
may be low due to the relative within-group homogeneity 
of the study sample (Flanigan, McFarlane, & Cook, 2008; 
Kellerman & Herold, 2001). Free text answers helped to 
explain the quantitative outcomes and added to the 
credibility of the data. 
In one previous study, the incidence of multifollicular 
development (defined as three or more follicles 14 mm) 
was reported as 17% in normo-ovulatory women and 6% 
in the ovulatory dysfunction group, resulting in 56 of 425 
cycles (13.2%) being cancelled (Coughlan, Fitzgerald, 
Milne, & Wingfield, 2010). All the reported multiple 
pregnancies occurred with unifollicular development, 
while TVUS evidence of multiple follicles did not 
necessarily correlate with multiple pregnancy. 
NICE gives no specific indication regarding the size or 
number or follicles that should be considered significant 
when scanning. Our survey found that the lowest cut-off 
follicular diameter quoted in local guidelines was 12 mm. 
Dickey and Holtkamp (1996) advised that all follicles down 
to 10 mm diameter should be considered when monitoring 
multiple pregnancy risk. They also reported that while the 
average number 12 mm diameter seen each cycle is 2.3, 
the optimum response to treatment is seen with at least 
four follicles. According to local guidelines quoted in the 
survey responses, a finding of three or four follicles would 
prompt advice to the patient to abstain from intercourse, 
therefore possibly denying them the optimum treatment 
effect. 
NICE does suggest scanning in the first cycle of 
clomifene only, assuming that women are at the greatest 
risk of overstimulation when first exposed to the 
medication. The relevance of scanning the first cycle to 
ensure safety in subsequent cycles is not well researched 
or understood. There can be a cumulative effect of 
clomifene from one cycle to the next, given its half-life of 
5–7 days (Mikkelson et al., 1986; Weller, Daniel, Koren, 
Lunenfeld, & Levy, 2017), and women can have 
significantly different responses between cycles (Coughlan 
et al., 2010). There can also be inconsistent responses to a 
particular dose between patients, suggesting that follicular 
development cannot be safely predicted based on a first-
cycle scan. 
Cost effectiveness has not been formally assessed 
regarding clomifene monitoring with TVUS. Resource 
limitations and access to TVUS are having a significant 
impact on the management of patients taking clomifene, 
based on their location. However, 33.8% of clinicians 
surveyed who have immediate access to TVUS are not 
always using it, suggesting that factors other than 
resources contribute to non-adherence with this guideline. 
Serum mid-luteal progesterone levels provide a reliable 
indicator of ovulation where it has occurred but give no 
information about multiple pregnancy risk. In a study 
where 75.3% of participants received clomifene, 
monitoring cycles using progesterone levels only was 
found to be effective with a multiple pregnancy rate of 
4.6% (Stanford, Parnell, & Boyle, 2008). We saw a weak 
negative correlation between TVUS and serum 
progesterone use, which may be partly explained by the 
high number of respondents checking progesterone levels 
regardless of their TVUS use. However, of the 24 
respondents who stated that they never scan, 21 were 
  
always using serum mid-luteal progesterone levels. A 
blood test may therefore be considered a viable alternative 
by clinicians who opt not to scan. 
In conclusion, the diverse responses to our survey 
indicate a continued clinical uncertainty and variation in 
practice despite the presence of a national guideline. This 
suggests a need for further evidence. The authors intend 
to conduct a feasibility cohort study and cost effectiveness 
analysis to compare outcomes associated with TVUS 
versus serum midluteal progesterone monitoring during 
clomifene therapy. If serum mid-luteal progesterone 
monitoring is shown to be at least equivalent to first-cycle 
TVUS monitoring of clomifene, this will likely challenge the 
need for invasive testing, and potentially reduce 
unnecessary cycle cancellations and subsequent 
progression to IVF. Conversely, if TVUS during first-cycle 
treatment is found to be appropriate, an evidence base will 
be available to reinforce the current national guideline. 
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